Reply

Journal of Allergy and Clinical Immunology

Volumn 128, Issue 2, 2011, Pages 430-432

  Blaiss, Michael ^a   Nelson, Harold S ^b   Durham, Stephen R ^c   Dahl, Ronald ^d   Bufe, Albrecht ^e  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC AGENT;

ALLERGY; DRUG EFFICACY; GRASS ALLERGY; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; LETTER; PLACEBO EFFECT; PRIORITY JOURNAL; SCORING SYSTEM; TABLET FORMULATION; TREATMENT OUTCOME;

EID: 79960996988     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.04.053     Document Type: Letter

References (9)

1. Kette F, Smith W. Sublingual immunotherapy: allergen specific or placebo effect? J Allergy Clin Immunol 2011;128:430.
2. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71, e4.
3. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80, e2.
4. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73, e7.
5. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40. (Pubitemid 44160721)
6. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-90. (Pubitemid 43381828)
7. Durham SR, Birk AO, Andersen JS. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Allergy 2011;66:120-3.
8. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9.
9. Durham SR, Dahl R, Kapp A, Colombo G, DeMonchy JGR, Rak S, et al. Sustained, disease-modifying effect of grass allergen tablet immunotherapy 2 years after end of treatment. Paper presented at: European Academy of Allergology and Clinical Immunology; June 5-9, 2010; London, United Kingdom.